Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL-37

Department of Pulmonology, C3-P, Leiden University Medical Center, P.O. Box 9600, 2300, RC Leiden, The Netherlands.
Inflammation Research (Impact Factor: 2.35). 04/2006; 55(3):119-27. DOI: 10.1007/s00011-005-0062-9
Source: PubMed


The aim of this study was to investigate the mechanisms of cell death mediated by the antimicrobial peptides neutrophil defensins (human neutrophil peptides 1-3 [HNP1-3]) and LL-37.
HNP1-3- and LL-37-mediated cell death was assessed in human lung epithelial cells and Jurkat T-cells in serum-free culture media.
Both HNP1-3 and LL-37 induced cell death in Jurkat T-cells and A549 cells. HNP1-3 but not LL-37 induced caspase-3/-7 activity and caused cleavage of [ADP-ribose] polymerase (PARP) in Jurkat cells, while in A549 cells neither peptides induced caspase-3/-7 activation. Furthermore, both peptides increased mitochondrial cytochrome c release in A549 and Jurkat cells. Our observation that over-expression of the anti-apoptotic protein Bcl-2 in Jurkat cells did not affect HNP1-3- or LL-37-induced cell death indicates that antimicrobial peptide-induced cytochrome c release is not involved in peptide-induced cell death. Finally, in A549 cells and in primary bronchial epithelial cells, both HNP1-3 and LL-37 induced DNA breaks as demonstrated by increased TUNEL labelling.
The results from this study suggest that the antimicrobial peptides HNP1-3 and LL-37 induce cell death, which is associated with mitochondrial injury and mediated via different intracellular pathways.

Download full-text


Available from: Dennis K Ninaber,
  • Source
    • "Unlike HNP-1, a known antimicrobial peptide that induces cytotoxicity at high concentrations in the absence of serum [1], the cytotoxic effect of HD5 has not been reported previously. HNPs can induce apoptosis leading to cell death [36]. To delineate the mechanism of HD5-mediate cytotoxicity in primary CD4+ T cells under serum-deprived condition, PHA-activated CD4+ T cells were cultured in 0.3%HS, ITS, and IL-2 in the presence or absence of HD5. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously shown that human defensin 5 (HD5) promotes HIV infectivity in both primary CD4+ T cells and HeLa cells expressing CD4 and CCR5. HD5 is induced in response to sexually transmitted infections (STIs) such as Chlamydia trachomatis and Neisseria gonorrhoeae, suggesting it plays a role in STI-mediated enhancement of HIV transmission. In contrast to our findings, a recent study reports that HD5 has an anti-HIV effect in primary CD4+ T cells under serum-deprived conditions. To resolve these apparently contradictory observations, we investigated experimental parameters that might contribute to contrasting effects of HD5. Serum-deprived culture conditions were associated with anti-HIV activity. In contrast to the dependence of the HIV enhancing effect on HD5 structure, the anti-HIV activity in serum-deprived primary CD4+ T cells was independent of HD5 structure as the linear peptide [Abu] HD5 exhibited similar anti-HIV activity. Under serum deprived conditions, HD5 blocked CD4-receptor-independent HIV-1vsv infection before or after viral entry. We found that HD5 and its linear form induced significant cell death in primary CD4+ T cells under serum-deprived culture conditions. HD5-mediated apoptosis was observed as early as 2 h after addition of defensins to serum-deprived primary CD4+ T cells. In contrast to primary CD4+ T cells, HD5 did not induce cytotoxicity and promote HIV infectivity of HeLa-CD4-CCR5 cells under serum-deprived conditions. These results indicate that under serum-deprived culture conditions HD5 is toxic for primary CD4+ T cells, warranting caution in data interpretation.
    PLoS ONE 09/2013; 8(9):e76038. DOI:10.1371/journal.pone.0076038 · 3.23 Impact Factor
  • Source
    • "However, at lower doses, HNP1–3 can also increase the proliferation, motility and invasiveness of cancer cell lines [87,89]. HNP-1 is oncolytic against several cancer cell lines, including Raji human B-lymphoma cells, human oral squamous carcinoma cells, and MOT mouseteratocarcinoma cells [10,11,79,90]. In addition, concentrations of HNP1–3 higher than 25 μg/mL exert cytotoxic effects on both eukaryotic cells and cancer cell lines [10,79,88,90], and the presence of α-defensins in tumor cells explored by immunohistochemistry is sometimes associated with morphological signs of necrosis in surrounding cells [88]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer continues to be a leading source of morbidity and mortality worldwide in spite of progress in oncolytic therapies. In addition, the incidence of cancers affecting the breast, kidney, prostate and skin among others continue to rise. Chemotherapeutic drugs are widely used in cancer treatment but have the serious drawback of nonspecific toxicity because these agents target any rapidly dividing cell without discriminating between healthy and malignant cells. In addition, many neoplasms eventually become resistant to conventional chemotherapy due to selection for multidrug-resistant variants. The limitations associated with existing chemotherapeutic drugs have stimulated the search for new oncolytic therapies. Host defense peptides (HDPs) may represent a novel family of oncolytic agents that can avoid the shortcomings of conventional chemotherapy because they exhibit selective cytotoxicity against a broad spectrum of malignant human cells, including multi-drug-resistant neoplastic cells. Oncolytic activity by HDPs is usually via necrosis due to cell membrane lysis, but some HDPs can trigger apoptosis in cancer cells via mitochondrial membrane disruption. In addition, certain HDPs are anti-angiogenic which may inhibit cancer progression. This paper reviews oncolytic HDP studies in order to address the suitability of selected HDPs as oncolytic therapies.
    International Journal of Molecular Sciences 12/2011; 12(11):8027-51. DOI:10.3390/ijms12118027 · 2.86 Impact Factor
  • Source
    • "Host cell cytotoxicity has been shown for LL-37 [14] which, like Aβ [79], is cytotoxic towards vascular smooth muscle cells. AMP host cell cytoxicity often involves disruption of mitochondrial function, an activity reported for both LL-37 [80], [81] and Aβ [27]. Thus, neurotoxicity that has been shown for Aβ is consistent with AMP behavior. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The amyloid beta-protein (Abeta) is believed to be the key mediator of Alzheimer's disease (AD) pathology. Abeta is most often characterized as an incidental catabolic byproduct that lacks a normal physiological role. However, Abeta has been shown to be a specific ligand for a number of different receptors and other molecules, transported by complex trafficking pathways, modulated in response to a variety of environmental stressors, and able to induce pro-inflammatory activities. Here, we provide data supporting an in vivo function for Abeta as an antimicrobial peptide (AMP). Experiments used established in vitro assays to compare antimicrobial activities of Abeta and LL-37, an archetypical human AMP. Findings reveal that Abeta exerts antimicrobial activity against eight common and clinically relevant microorganisms with a potency equivalent to, and in some cases greater than, LL-37. Furthermore, we show that AD whole brain homogenates have significantly higher antimicrobial activity than aged matched non-AD samples and that AMP action correlates with tissue Abeta levels. Consistent with Abeta-mediated activity, the increased antimicrobial action was ablated by immunodepletion of AD brain homogenates with anti-Abeta antibodies. Our findings suggest Abeta is a hitherto unrecognized AMP that may normally function in the innate immune system. This finding stands in stark contrast to current models of Abeta-mediated pathology and has important implications for ongoing and future AD treatment strategies.
    PLoS ONE 03/2010; 5(3):e9505. DOI:10.1371/journal.pone.0009505 · 3.23 Impact Factor
Show more